CD14++CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients

Kidney International

Volumn 73, Issue 5, 2008, Pages 622-629

  Heine, G H ^a   Ulrich, C ^a   Seibert, E ^a   Seiler, S ^a   Marell, J ^a   Reichart, B ^a   Krause, M ^a   Schlitt, A ^b   Kohler H ^a   Girndt, M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Atherosclerosis; Dialysis; Epidemiology; Immunology; Outcomes

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL TYPE; COHORT ANALYSIS; DEATH; DIALYSIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEART DEATH; HIGH RISK POPULATION; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

EID: 39349086778     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002744     Document Type: Article

References (36)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
2. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-1927.
3. Sarnak MJ, Coronado BE, Greene T et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327-335.
4. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14: 1927-1939.
5. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
6. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16: S83-S88.
7. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1745.
8. Caravaca F, Martin MV, Barroso S et al. Do inflammatory markers add predictive information of death beyond that provided by age and comorbidity in chronic renal failure patients? Nephrol Dial Transplant 2006; 21: 1575-1581.
9. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-1226.
10. Getz GS. Thematic review series: the immune system and atherogenesis. immune function in atherogenesis. J Lipid Res 2005; 46: 1-10.
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
12. Lee CD, Folsom AR, Nieto FJ et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and white men and women: atherosclerosis risk in communities study. Am J Epidemiol 2001; 154: 758-764.
13. Grau AJ, Boddy AW, Dukovic DA et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35: 1147-1152.
14. Wheeler JG, Mussolino ME, Gillum RF et al. Associations between differential leukocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J 2004; 25: 1287-1292.
15. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627-636.
16. Johnson DW, Wiggins KJ, Armstrong KA et al. Elevated white cell count at commencement of peritoneal dialysis predicts overall and cardiac mortality. Kidney Int 2005; 67: 738-743.
17. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245.
18. Reddan DN, Klassen PS, Szczech LA et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 1167-1173.
19. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
20. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211: 609-618.
21. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-592.
22. Tacke F, Alvarez D, Kaplan TJ et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
23. Sester U, Sester M, Heine G et al. Strong depletion of CD14(+)CD16(+) monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402-1408.
24. Schlitt A, Heine GH, Blankenberg S et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004; 92: 419-424.
25. Gosling J, Slaymaker S, Gu L et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103: 773-778.
26. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
27. Smith JD, Trogan E, Ginsberg M et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (Op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8268.
28. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-2534.
29. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-592.
30. Ancuta P, Rao R, Moses A et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
31. Braunersreuther V, Zernecke A, Arnaud C et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27: 373-379.
32. Zernecke A, Liehn EA, Gao JL et al. Deficiency in CCR5 but Not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 2006; 107: 4240-4243.
33. Ulrich C, Heine GH, Garcia P et al. Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease. Nephrol Dial Transplant 2006; 21: 1596-1602.
34. Qu C, Edwards EW, Tacke F et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med 2004; 200: 1231-1241.
35. Landsman L, Varol C, Jung S. Distinct differentiation potential of blood monocyte subsets in the lung. J Immunol 2007; 178: 2000-2007.
36. Strauss-Ayali D, Conrad SM, Mosser DM. Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol 2007; 82: 244-252.